Ingredient comparison Nº 18 / Head-to-head
Kojic Acid vs Alpha-Arbutin
Both inhibit tyrosinase, but kojic acid is more potent and less stable; alpha-arbutin is gentler, more stable, and better tolerated for long-term use.
Kojic acid and alpha-arbutin are both tyrosinase inhibitors used for hyperpigmentation, dark spots, and melasma, but they differ significantly in potency, stability, and sensitisation risk. Kojic acid inhibits tyrosinase via direct copper chelation at the enzyme's active site — a well-established and relatively potent mechanism with 12-week clinical evidence showing 58% MASI reduction at 1% monotherapy. Its main limitations are chemical instability (oxidises and turns brown in aqueous formulations) and a documented contact sensitisation rate higher than gentler brighteners. Alpha-arbutin inhibits tyrosinase via competitive inhibition at the substrate-binding site, is approximately 20-fold more potent than beta-arbutin against human tyrosinase, is substantially more stable in formulation, and is very well tolerated across skin types. The EU SCCS has set safety concentration limits for both. The choice depends on skin sensitivity, tolerance for product instability, and whether the sensitisation risk of kojic acid is a concern.
02 / Head-to-head
Compared dimension by dimension
Each row shows what the evidence actually says for both ingredients on that dimension. Edge = which ingredient has the stronger case, or "no clear edge" when evidence is comparable or insufficient for a call.
| Dimension | Kojic Acid | Alpha-Arbutin | Edge |
|---|---|---|---|
| Tyrosinase inhibition mechanism | Copper chelation at tyrosinase's catalytic site — slow-binding competitive inhibition.Directly removes copper ions required for enzymatic function. Kinetics: rapid formation of enzyme-inhibitor complex followed by slow reversible isomerisation. 1 | Competitive inhibition at the L-tyrosine substrate-binding site.Does not affect tyrosinase mRNA expression or melanocyte viability — the mechanism is purely enzymatic inhibition without cytotoxicity. Approximately 20-fold more potent than beta-arbutin against human tyrosinase. 1314 | No clear edge |
| Clinical evidence for hyperpigmentation | 1% monotherapy: 58% MASI reduction at 12 weeks in a randomised, single-blind trial (n=60).2% in combination with hydroquinone and glycolic acid: 60% complete clearance vs 47.5% for the control arm in a split-face RCT (n=40). 23 | A prospective study (n=124, Indian women with melasma, Fitzpatrick III–IV) using alpha-arbutin combined with trihydroxybenzoic acid glucoside and sunscreen showed 16.3% melanin reduction and 18.4% mMASI improvement at 90 days. No standalone monotherapy RCT for alpha-arbutin alone has been published. 17 | Advantage: Kojic Acid |
| Formulation stability | Chemically unstable in aqueous formulations.Oxidises on exposure to light, air, and iron ions (Fe3+), producing yellow-then-brown discolouration — a direct indicator of potency loss. Emulgel and microemulsion formats improve stability. Opaque, airless packaging required. 45 | Substantially more stable.Cream formulations at pH 4.0 and 5.5 retained approximately 92% active ingredient after 60 days across temperatures up to 40°C. No significant oxidative degradation under cosmetic storage conditions. No airless packaging required. 16 | Advantage: Alpha-Arbutin |
| Contact sensitisation risk | Higher sensitisation rate than gentler brighteners.Patch test studies: 5 of 8 patients using kojic acid products tested positive for allergic contact dermatitis; 7.8% positive rate in separate European dermatology populations. Paradoxical pigmented contact dermatitis (darkening from a lightening agent) has been reported. 678 | Very well tolerated across skin types at cosmetic concentrations (≤2%).No skin sensitisation was identified in SCCS safety evaluations. The EU SCCS found no evidence of sensitisation, carcinogenicity, or reproductive toxicity at cosmetic use concentrations. 15 | Advantage: Alpha-Arbutin |
| Regulatory limits (EU SCCS) | EU SCCS SCCS/1637/21 (2022): safe up to 1% in leave-on face creams and body lotions.CIR (2010): safe at concentrations where sensitisation effects do not occur. The EU limit constrains formulation headroom. 910 | EU SCCS SCCS/1642/22 (2023): safe at ≤2% in face creams and ≤0.5% in body lotions.The 2% ceiling doubles the formulation headroom relative to kojic acid's 1% EU cap. 15 | Advantage: Alpha-Arbutin |
| Hydroquinone relation / safety profile | Kojic acid is not structurally related to hydroquinone.The primary safety concern is contact sensitisation and, at very high oral dietary doses in animal studies, non-genotoxic tumour induction — not relevant at topical 1%. Mouse skin topical studies found no carcinogenic or photo-genotoxic activity. 1211 | Alpha-arbutin is a hydroquinone glucoside.In principle it can hydrolyse to release free hydroquinone. The SCCS evaluated this risk and confirmed the margin of safety is acceptable at ≤2% face / ≤0.5% body. The alpha-glycosidic bond is more resistant to enzymatic hydrolysis than beta-arbutin. 1518 | No clear edge |
03 / The decision
Which one is right for you?
Choose Kojic Acid if…
- You want a stronger tyrosinase inhibitor with more robust monotherapy MASI-score clinical evidence and have already tolerated it well in prior use
- You are targeting moderate-to-severe hyperpigmentation or melasma and want the most potent OTC tyrosinase inhibitor — kojic acid at 1% has the stronger monotherapy trial record
- You understand the stability limitations and purchase from brands using opaque, airless packaging and appropriate antioxidant co-ingredients
- Your skin is not sensitive and you have not previously experienced contact dermatitis from skincare actives
Choose Alpha-Arbutin if…
- You have sensitive skin or a history of contact sensitisation from skincare — alpha-arbutin has a significantly lower sensitisation rate than kojic acid
- You want a stable brightening active that will not degrade to an inactive brown residue before you finish the bottle
- You prefer a higher formulation ceiling (up to 2% EU-permitted) with better safety margin versus kojic acid's 1% EU cap
- You have darker skin tones (Fitzpatrick III–VI) where sensitisation-triggered post-inflammatory hyperpigmentation is a higher-stakes risk
- You want a brightener you can combine with other actives — alpha-arbutin's broader stability and tolerability make multi-ingredient layering easier
Shop these actives
Buy Kojie San on Amazon $9.93 Kojic Acid · affiliate link
Buy The Ordinary on Amazon $11.50 Alpha-Arbutin · affiliate link
04 / Stacking
Can you use both?
Can you combine Kojic Acid and Alpha-Arbutin?
Kojic acid and alpha-arbutin can be used in the same routine and are sometimes combined in multi-brightener formulations targeting different tyrosinase inhibition pathways (copper chelation vs substrate competition). However, because both are hydroquinone-pathway brighteners, combined use should be considered thoughtfully. The EU SCCS explicitly noted that combined use of alpha-arbutin with other hydroquinone-releasing substances was not fully evaluated in its safety opinions (SCCS/1552/15). The practical approach: use one or the other as the primary tyrosinase inhibitor, and layer with a mechanistically distinct brightener (niacinamide, tranexamic acid) for complementary action.
05 / Questions
Frequently asked
- Kojic acid vs alpha-arbutin — which is more effective for dark spots?
- Kojic acid has stronger monotherapy clinical trial evidence: 1% monotherapy achieved 58% MASI reduction at 12 weeks in a randomised trial (n=60). Alpha-arbutin's clinical evidence comes from a combination formulation study (n=124) showing 16.3% melanin reduction at 90 days — no standalone monotherapy RCT exists. On raw evidence, kojic acid has the more direct efficacy record. However, alpha-arbutin is approximately 20-fold more potent than beta-arbutin against human tyrosinase in vitro, and its stability and tolerability advantages mean the delivered dose is more reliable. The honest answer: kojic acid has stronger standalone efficacy data, alpha-arbutin has a better stability and safety profile. 21714
- Is kojic acid or alpha-arbutin safer for sensitive skin?
- Alpha-arbutin is considerably safer for sensitive skin. Kojic acid has a documented contact sensitisation rate with patch test positivity in a subset of users; paradoxical pigmented contact dermatitis has also been reported. These sensitisation events can worsen the hyperpigmentation you are trying to treat. Alpha-arbutin at ≤2% was found free of sensitisation signals in EU SCCS safety evaluations. For sensitive skin, reactive skin, or anyone who has previously experienced contact dermatitis from skincare actives, alpha-arbutin is the strongly preferred brightener. 6815
- Why does kojic acid turn brown?
- Kojic acid oxidises in aqueous formulations when exposed to light, air (dissolved oxygen), and especially iron ions (Fe3+). The iron-catalysed oxidation produces yellow-to-brown chelate complexes — a visible indicator that the ingredient has degraded and lost potency. This is analogous to an L-ascorbic acid serum turning orange-brown. A discoloured kojic acid product has meaningfully less active ingredient than intended and should be discarded. Microemulsion and emulgel formats significantly improve photostability; opaque, airless packaging slows oxidation. 45
06 / References
Sources
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18